2 Biotechs on Watch After CBLI Exploded

[RagingBull All-Access] Dear Trader— Jeff Bishop here, At RagingBull this week, we’ve been exploring themes around trading stocks of lower market cap, specifically penny stocks. They’re a way to capture impressive gains, without ever even needing to touch an options contract. Jeff Williams just went LIVE today to share his strategy to trade them— and if you missed the event, [you can catch the replay here.]( Today, we want to share how a hot penny stock just popped off in the biotech sector, and reveal what biotechs one of our other traders— Kyle Dennis— is looking into. [I'm an image] Cleveland Biolabs (CBLI) was the hottest stock yesterday. Shares almost doubled before the market even opened— from $2.5 in the premarket to $5.43 during the trading day. Here’s what happened: Cleveland BioLabs, which focuses on novel approaches to activate the immune system, announced a strategic merger with Cytocom Inc. in an all-stock deal on Monday evening. In the early premarket session on Tuesday, the stock was at $2.7, up only 25% from the prior close of $2.16. At 7:30 am it was already at $4.4, up 103% After the open, the stock rallied one more time, putting in the high of $5.43 and reaching over 250% gain from the previous day’s close. It wasn’t a smooth ride up though. Here’s what the full day looked like: [Alternate text] There were three good risk reward trades there: [Alternate text] All the variables lined up for a huge runup— a biotech stock with fresh news and a float of 5.7M shares. Hindsight is always 20/20, but next time try to recognize these spots while they are happening. As Jeff Williams mentioned in his LIVE event today, he’s about to kick off[his next small account challenge]( where he tries to hunt down big movers like these. [Download his penny stock traders starter pack here]( to get a taste of his strategy. [Alternate text]( [Alternate text] Jeff Willaims isn’t the only one after stocks like Cleveland Biolabs (CBLI). As you might be well aware by now, Kyle Dennis’ core strategy focuses on catalyst driven biotech plays. People often get scared when they hear about trading biotechs into data readouts. See, news of that kind are often a “binary event.” Meaning... once the stock un-halts from the announcement, it’s either up a lot, or down a lot— with not much opportunity for risk-managed trading. This is where Kyle Dennis’s strategy comes in very handy— he doesn’t just bet on black (or red) and wait for the spin. He takes advantage of the moves leading into big announcements. In weeks and months before the readout, you'd often see a stock drift lower when traders bet short or offload the risk, not anticipating good data. The same is true on the other side— excited companies get bought sky high. By focusing on these “anticipation moves,” Kyle’s strategy combines high volatility of biotechs with sound risk-management. Now, granted, you need to know what’s happening before you trade something like that. [The watchlist Kyle puts out every week]( teaches traders how to spot these anticipation moves. He provides you with cherry picked technical setups, well-paired with highly-anticipated news announcements. Below, we present to you 2 of Kyle’s latest stock picks: Eiger Biopharmaceuticals - EIGR - A Biotech company focused on developing therapies for rare and ultra-rare diseases - As of lately, the company has also been working on a coronavirus therapy in a joint effort with University of Toronto with promising data reported on 10/15 - More in focus, however, is the PDUFA date of 20th of November. The company expects a priority review decision from FDA on Lonafamib, it’s Progeria drug candidate Going into the announcement, our play is as follows: - Buy Zone: 10.10 to 10.60 - Profit Zone: 11.50 or higher - Stop Zone: 9.75 or below Options: EIGR November 20 12.50 Calls EIGR chart, 6-month, daily [Alternate text] Aptose - APTO - A clinical stage biotech company developing cancer targeting therapies - On December 5th, the company plans to release important updates on its lead drug candidate— CG806— trialed for treatment of leukemia and Non-Hodgkin's lymphoma Going into the announcement, our play is as follows: - Buy Zone: 5.50 to 5.90 - Profit Zone: 6.30 or higher - Stop Zone: 5.20 or below Options: No options APTO chart, 6-month, daily: [Alternate text] Kyle will provide[his freshest updates here on exactly how he’s trading EIGR and APTO](— in the case that he does trade them. [Alternate text] If the stocks on today’s watchlist sound exciting to you, just know there’s also a whole lot of proof in the pudding. Kyle recently passed $10,000,000 in total trading profits. You read that right, $10 million. Kyle shares a whole lot of helpful insights in his most recent interview with WealthWise host, Ben Sturgill, including... - What he would have told his younger self, as he first started trading - What it took to get to $10 million in trading - How he handles losses - The emotions of trading and how to manage them - What happened when he initially lost half his trading account! - The #1 thing he did to start heading toward $10 million [Alternate text] [Check out the podcast episode here.]( ) [Alternate text] [This One Chart Signals Strength In The Markets]( By JC Parets of Chart Hunter [Alternate text]( [3 Reasons Why I Went Flat]( By Nathan Bear of Weekly Money Multiplier [Alternate text]( [Catalyst Trading 101]( By Kyle Dennis of Biotech Breakouts [Alternate text]( [Is This The Next Small-Cap Sector To Break Out?]( By Jason Bond of Jason Bond Picks [Alternate text]( RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from support@ragingbull.com]( [Unsubscribe from all RagingBull emails]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website,application or other service ("Services"), please review our full disclaimer located at [(disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication.